Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-Pentetreotide scintigraphy
- 1 February 2005
- journal article
- Published by Elsevier in Revista Española de Medicina Nuclear
- Vol. 24 (1), 14-18
- https://doi.org/10.1157/13070352
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumoursClinical Endocrinology, 2003
- SPECT/CT in tumor imaging: Technical aspects and clinical applicationsSeminars in Nuclear Medicine, 2003
- Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasmsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results.European Journal of Nuclear Medicine and Molecular Imaging, 1998
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993